Recent Advance in Targeted Therapy in Medicine

Dear Colleagues,

Targeted therapy has become one of the main cancer management modalities and is further developing at a rapid pace. The realm of target molecules is expanding; these targets concern carcinogenesis, cell cycle and tumour growth, angiogenesis, and tumour microenvironments. Currently, targets at the systemic level, such as signal transduction molecules, inflammatory cytokines, and their receptors, have also been identified. The original proposed advantage to these targets is that targeted therapy can be more effective than cytotoxic chemotherapeutics. At the same time, targeted therapy is expected to have a huge reduction in the undesirable side effects (compared with chemo-drug treatments’).

Targeted therapeutic agents have been designed and have been mainly used in clinic settings for a number of cancers (e.g., multiple myeloma, breast cancer, prostate cancer, colon cancer, melanoma, lung cancer, liver cancer, brain tumors, ovarian cancer, and pancreatic cancers). There are different approaches for targeted therapy in cancer treatment, including utilizing inhibitors against certain specific molecules in signal transduction, tumor cell growth or angiogenesis; hormone therapies for hormone-sensitive tumors, and immunotherapies for specific cancer cells. The purpose of this Special Issue is to highlight our current knowledge on the clinical efficacy and side-effects of the various forms of targeted therapy in this endeavor of creating a "preferred" cancer management approach for the multiple cancer types mentioned above. The Special Issue will cover the following subtopics:

Subtopics covered:

• Clinical Efficacy and Side Effects of Targeted therapy
• Patient's Quality of Life in Using Targeted Therapy
• Immunological Effects of Targeted Therapy
• Nanocarriers as Novel Delivery Platforms for Targeted Therapy
• Targeted Therapy Against Cancer Stem Cells
• New Promising Molecular Targets for Therapeutics
• New Molecular Target for Disease Diagnosis
• Management of Target Drug Resistance

Dr. Daniel M.-Y. Sze
Dr. William Chi-shing Cho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.